A risk model for non-small cell lung cancer using clinicopathological variables, angiogenesis and oncoprotein expression

Anticancer Research

Volumn 25, Issue 1 B, 2005, Pages 497-504

  Rubio, L ^a   Vera Sempere, F J ^a   Lopez Guerrero, J A ^b   Padilla, J ^a   Moreno Baylach, M J ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Angiogenesis; iNOS; Lung cancer; Oncoprotein; Risk model; VEGF

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; CYCLIN DEPENDENT KINASE INHIBITOR 1; INDUCIBLE NITRIC OXIDE SYNTHASE; ONCOPROTEIN; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER RISK; CANCER STAGING; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; MODEL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR; TUMOR VOLUME; VASCULARIZATION;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FACTOR VIII; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MODELS, THEORETICAL; MULTIVARIATE ANALYSIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PROGNOSIS; RISK; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 16344387665     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. D'Amico TA, Massey M, Herndon II JE, Moore MB and Harpole DH: A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 117: 736-743, 1999.
2. Herbst RS and Fiedler IJ: Angiogenesis and lung cancer: potential for therapy. Clin Cancer Res 6: 4604-4606, 2000.
3. Duarte IG, Bufkin BL, Pennington MF, Gal AA, Cohen C, Kosinski AS, Mansour KA and Miller JI: Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung carcinoma. J Thorac Cardiovasc Surg 115: 652-659, 1998.
4. Fontanini G, Lucchi M, Vignati S, Mussi A, Ciardiello F, De Laurentiis M, De Placido S, Basolo F, Angeletti CA and Bevilacqua G: Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst 89: 881-886, 1997.
5. Cox G, Jones JL, Andi A, Waller DA and O'Byrne KJ: A biological staging model for operable non-small cell lung cancer. Thorax 56: 561-566, 2001.
6. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990.
7. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
8. Rubio L, Burgos JS, Morera C and Vera-Sempere FJ: Morphometric study of tumor angiogenesis as a new prognostic factor in nasopharyngeal carcinoma patients. Pathol Oncol Res 6: 210-216, 2000.
9. Korkolopoulou P, Konstantinidou AE, Kavantzas N, Patsouris E, Pavlopoulos PM, Christodoulou P, Thomas-tsagli E and Davaris P: Morphometric microvascular characteristics predict prognosis in superficial and invasive bladder cancer. Virchows Arch 438: 603-611, 2001.
10. Fontanini G, Bigini D, Vignati S, Basolo F, Mussi A, Lucchi M, Chiné S, Angeletti CA, Harris AL and Bevilacqua G: Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol 177: 57-63, 1995.
11. Fontanini G, Vignati S, Boldrini L, Chiné S, Silvestri V, Lucchi M, Mussi A, Angeletti CA and Bevilacqua G: Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 3: 861-865, 1997.
12. Masuya D, Huang C-L, Liu D, Kameyama K, Hayashi A, Yamauchi A, Kobayashi S, Haba R and Yokomise H: The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in non small cell lung carcinoma patients. Cancer 92: 2628-2638, 2001.
13. Han H, Silverman JF, Santucci TS, Macherey RS, d'Amato TA, Tung MY, Weyant RJ and Landreneau RJ: Vascular endothelial growth factor expression in stage I non small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 8: 72-79, 2001.
14. Brennan PA, Umar T, Wilson AW and Mellor TK: Expression of type 2 nitric oxide synthase and vascular endothelial growth factor in oral dysplasia. J Oral Maxillofac Surg 60: 1455-1460, 2002.
15. 15 Marrogi AJ, Travis WD, Welsh JA, Khan MA, Rahim H, Tazelaar H, Pairolero P, Trastek V, Jett J, Caporaso NE, Liotta LA and Harris CC: Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 6: 4739-4744, 2000.
16. Song Z-J, Gong P and Wu YE: Relationship between the expression of iNOS, VEGF, tumor angiogenesis and gastric cancer. World J Gastroenterol 8: 591-595, 2002.
17. Matsumoto M, Furihata M, Kurabayashi A, Araki K, Sasaguri S and Ohtsuki Y: Association between inducible nitric oxide synthase expression and p53 status in human esophageal squamous cell carcinoma. Oncology 64: 90-96, 2003.
18. Pukkila MJ, Kellokoski JK, Virtaniemi JA, Kumpulainen EJ, Johansson RT, Halonen PM, Kosunen AS, Nuutinen J and Kosma VM: Inducible nitric oxide synthase expression in pharyngeal squamous cell carcinoma: relation to p53 expression, clinicopathological data, and survival. Laryngoscope 112: 1084-1088, 2002.
19. Sherr CJ: The pezcoller lecture: cancer cell cycles revisited. Cancer Res 60: 3689-3695, 2000.
20. Ng CC, Arakawa H, Fukuda S, Kondoh H and Nakamura Y: p53RFP, a p53-inducible RING-finger protein, regulates the stability of p21WAF1. Oncogene 22: 4449-4458, 2003.
21. Caputi M, Esposito V, Baldi A, De Luca A, Dean C, Signoriello G, Baldi F and Giordano A: P21 waf1/cip1 mda-6 expression in non-small-cell lung cancer: relationship to survival. Am J Resp Cell Mol Biol 18: 213-217, 1998.
22. Niklinski J, Niklinska W, Laudanski J, Chyczewska E and Chyczewski L: Prognostic molecular markers in non-small cell lung cancer. Lung Cancer 34(suppl. 2): S53-58, 2001.
23. Komiya T, Hosono Y, Hirashima T, Masuda N, Yasumitsu T, Nakagawa K, Kikui M, Ohno A, Fukuoka M and Kawase I: P21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. Clin Cancer Res 3: 1831-1835, 1997.
24. Shoji T, Tanaka F, Takata T, Yanagihara K, Otake Y, Hanaoka N, Miyahara R, Nakagawa T, Kawano Y, Ishikawa S, Katakura H and Wada H: Clinical significance of p21 expression in non-small-cell lung cancer. J Clin Oncol 20: 3865-3871, 2002.
25. Yano S, Nishioka Y, Goto H and Sone S: Molecular mechanism of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules. Cancer Sci 94: 479-485, 2003.
26. Sridhar SS and Shepherd FA: Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 42 (suppl 1): S81-91, 2003.
27. Galligioni E and Ferro A: Angiogenesis and antiangiogenic agents in non-small cell lung cancer. Lung Cancer 34 (suppl. 4): S3-7, 2001.
28. Folkman J and Klagsbrun M: Angiogenic factors. Science 235: 442-447, 1987.
29. Campbell SC: Advances in angiogenesis research: relevance to urological oncology. J Urol 158: 1663-1674, 1997.
30. Giatromanolaki A: Prognostic role of angiogenesis in non-small cell lung cancer. Anticancer Res 21: 4373-4382, 2001.
31. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Chiné S, Angeletti CA and Bevilacqua G: Recurrence and death in non-small cell lung carcinomas: a prognostic model using pathological parameters, microvessel count, and gene protein products. Clin Cancer Res 2: 1067-1075, 1996.
32. Tsoli E, Zacharatos P, Dasiou-Plakida D, Peros J, Evangelou K, Zavras AI, Yannoukakos D, Konstantopoulou I, Asimacopoulos PJ, Kittas C and Gorgoulis VG: Growth index is independent of microvessel density in non-small cell lung carcinomas. Hum Pathol 33: 812-818, 2002.
33. Carbognani P, Tincani G, Crafa P, Sansebastiano G, Pazzini L, Zoni R, Bobbio A and Rusca M: Biological markers in non-small cell lung cancer. Retrospective study of 10 year follow-up after surgery. J Cardiovasc Surg 43: 545-548, 2002.
34. Galindo-Gallego M, Fernandez-Acenero MJ, Sanz-Ortega J, Aljama A and Lopez-Elzaurdia C: Prognostic significance of microvascular counts in rectal carcinoma. Pathol Res Pract 196: 607-612, 2000.
35. Qian CN, Min HQ, Liang XM, Zheng SS and Lin HL: Primary study of neovasculature correlating with metastatic nasopharyngeal carcinoma using computer image analysis. J Cancer Res Clin Oncol 123: 645-651, 1997.
36. Harpole DH, Herndon II JE, Wolfe WG, Iglehart JD and Marks JR: A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 55: 51-56, 1995.
37. Padilla J, Calvo V, Penalver JC, Zarza AG, Pastor J, Blasco E and Paris F: Survival and risk model for stage 1B non-small cell lung cancer. Lung Cancer 36: 43-48, 2002.
38. Yano T, Tanikawa S, Fujie T, Masutani M and Horie T: Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. Eur J Cancer 36: 601-602, 2000.
39. Ahn MJ, Jang SJ, Park YW, Choi JH, Oh HS, Lee CB, Paik HK and Park CK: Clinical prognostic values of vascular endothelial growth factor, microvessel density, and p53 expression in esophageal carcinomas. J Korean Med Sci 17: 201-207, 2002.
40. Park SH and Lee SS: The relationship between serum VEGF concentration and poor prognosis of lung cancer. Korean J Intern Med 18: 207-211, 2003.
41. Jenkins DC, Charles IG, Thomsen LL, Moss D, Holmes LS, Baylis SA, Rhodes P, Westmore K, Emson PC and Moncada S: Roles of nitric oxide in tumor growth. Proc Natl Am Sci 92: 4392-4396, 1995.
42. Vakkala M, Kahlos K, Lakari E, Pääkkö P, Kinnula V and Soini Y: Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in situ and invasive breast carcinomas. Clin Cancer Res 6: 2408-2416, 2000.
43. Fujimoto H, Ando Y, Yamashita T, Terazaki H, Tanaka Y, Sasaki J, Matsumoto M, Suga M and Ando M: Nitric oxide synthase activity in human lung cancer. Jpn J Cancer Res 88: 1190-1198, 1997.
44. Matlashewski G: p53: twenty years on, meeting review. Oncogene 18: 7618-7620, 1999.
45. May P and May E: Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 18: 7621-7636, 1999.
46. Meek MD: Mechanisms of switching on p53: a role for covalent modification? Oncogene 18: 7666-7675, 1999.
47. Passlick B, Izbicki JR, Häussinger K, Thetter O and Pantel K: Immunohistochemical detection of p53 protein is not associated with a poor prognosis in non-small-cell lung cancer. J Thorac Cardiovasc Surg 109: 1205-1211, 1995.
48. Fontanini G, Boldrini L, Vignati S, Chiné S, Basolo F, Silvestri V, Lucchi M, Mussi A, Angeletti CA and Bevilacqua G: Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma. Eur J Cancer 34: 718-723, 1998.
49. Giatromanolaki A, Koukourakis MI, Kakolyris S, Turley H, O'Byrne K, Scott PAE, Pezzella F, Georgoulias V, Harris LA and Gatter KC: Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res 4: 3017-3024, 1998.
50. Dameron KM, Volpert OV, Tainsky MA and Bouck N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582-1584, 1994.
51. Kwak C, Jin RJ, Lee C, Park MS and Lee SE: Thrombospondin-1, vascular endothelial growth factor and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia. B J U Int 89: 303-309, 2002.
52. Sargiannidou I, Qiu C and Tuszynski GP: Mechanisms of thrombospondin-1-mediated metastasis and angiogenesis. Semin Thromb Hemost 30: 127-136, 2004.
53. Tas F, Yavuz E, Aydiner A, Saip P, Disci R, Iplikci A and Topuz E: Angiogenesis and p53 protein expresion in breast cancer: prognostic roles and interrelationships. Am J Clin Oncol 23: 546-553, 2000.
54. Freemantle SJ: Clinical link between p53 and angiogenesis in lung cancer. J Clin Oncol 20: 883-884, 2002.
55. Tse V, Yung Y, Santelli JG, Juan D, Hsiao M, Haas M, Harsl G 4th and Silverberg G: Effects of tumor suppressor gene (p53) on brain tumor angiogenesis and expression of angiogenic modulators. Anticancer Res 24: 1-10, 2004.
56. Gomyo Y, Ikeda M, Osaki M, Tatebe S, Tsujitani S, Ikeguchi M, Kaibara N and Ito H: Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer 79: 2067-2072, 1997.
57. Scappaticci FA: Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 20: 3906-3927, 2002.
58. Rak J and Yu JL: Oncogenes and tumor angiogenesis: the question of vascular "supply" and vascular "demand". Semin Cancer Biol 14: 93-104, 2004.